Dr Jiri Pavlu Consultant haematologist
- 020 8383 8117 020 8383 5030
Dr Jiri Pavlu is a consultant haematologist at Hammersmith Hospital and honorary clinical senior lecturer at Imperial College, London. He has worked at Imperial College Healthcare NHS Trust for over a decade and is a specialist in haematopoietic cell transplantation and acute leukaemias. He graduated from the first faculty of medicine of Charles University in Prague in 1998. He carried out his research in molecular haematology at St George's Hospital Medical School in London and completed his specialist haematology training in London on the Royal Free and Hammersmith rotation. He is a member of the Royal College of Physicians and a fellow of the Royal College of Pathologists.
Dr Pavlu is a principal investigator and subinvestigator of various clinical trials and active member of the British Society of Blood and Marrow Transplantation (BSBMT) and European Group for Blood and Marrow Transplantation (EBMT).
Acute leukaemia (ALL and AML), Haematopoietic cell transplantation, Myelodysplastic syndromes
Research & publications
Stem cell and bone marrow transplantation, particularly for leukaemia.
Bain BJ, Heller M, Toma S, Pavlu Jet al., 2015, The cytological features of NPM1-mutated acute myeloid leukemia, American Journal of Haematology, Vol: 90, 560-560
Farah N, Szydlo R, Mitul P, Sridharan M, Sawhney H, Lasa M, Mccue J, Atkins M, Kanfer E, MacDonald D, Milojkovic D, Pavlu J, Olavarria E, Rahemtulla A, Chaidos A, Gabriel I, Apperley J et al., 2015, A Study to Validate the Rationale and Efficacy of a Pre-emptive approach to the management of Cytomegalovirus (CMV) reactivation post allogeneic haematopoietic stem cell transplantation (HSCT), 41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Publisher: Nature Publishing Group, S409-S410
Vanhinsbergh LJ, Fleming C, Babb A, Pavlu J, Al Obaidi M et al., 2015, Azacitidine use in North West London: an update, 55th Annual Scientific Meeting of the British-Society-for-Haematology, Wiley-Blackwell, 80-80
King C, Aylin P, Moore LSP, Pavlu J, Holmes A et al., 2014, Syndromic surveillance of surgical site infections - A case study in coronary artery bypass graft patients, Journal of Infection, Vol: 68, 23-31
Palani R, Lasa M, Giles C, Erblich T, Patel A, Ghorashian S, Bray E, Loaiza S, Bradshaw A, Finn S-A, Saleem A, Haynes R, Chaidos A, Auner H, Pavlu J, Milojkovic D, Macdonald D, Kanfer E, Apperley J, Rahemtulla A et al., 2014, High dose etoposide/GCSF is a safe and effective mobilisaton regimen in multiple myeloma: A single-institution experience, 40th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: Nature Publishing Group, S534-S534
Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K et al., 2014, Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia, Haematologica, Vol: 99, 836-847
Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E, Macdonald DH, Marin D, Milojkovic D, Pavlu J, Apperley JF, Rahemtulla A et al., 2013, Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation, Leukemia & Lymphoma, Vol: 54, 2200-2204
Auner HW, Szydlo R, Rone A, Giles C, Chaidos A, Kanfer EJ, Macdonald DH, Milojkovic D, Marin D, Pavlu J, Apperley JF, Rahemtulla A et al., 2013, Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation, Bone Marrow Transplantation, Vol: 48, S199-S199
Deplano S, May PC, Pavlu J, 2013, Double minutes with MYC amplification in a patient with chronic myelomonocytic leukaemia transformed into acute myeloid leukaemia, British Journal of Haematology, Vol: 162, Pages: 720-720
Gabriel IH, Sergeant R, Szydlo R, Apperley JF, Alsuliman A, Khoder A, Goldman J, Kanfer E, de Lavallade H, Miljokovic D, Rahemtulla A, Pavlu J, Foroni L, Marin D, Rezvani Ket al., 2013, Donor KIR2DS2/DL2 genotype status is associated with an increased incidence of severe acute graft-versus-host disease following myeloablative haematopoeitic stem cell transplantation, 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Nature Publishing Group: S19-S19